Dimensional Fund Advisors LP Purchases 263,623 Shares of PTC Therapeutics, Inc. $PTCT

Key Points

• Dimensional Fund Advisors increased its PTC Therapeutics stake by 42% in the first quarter, purchasing 263,623 additional shares and bringing its holdings to 890,715 shares valued at approximately $60.7 million.
• PTC Therapeutics reported second-quarter revenue of $360.5 million, up 101.5% year over year, and adjusted earnings of $0.92 per share versus the $0.24 analyst consensus. Strong Sephience sales helped drive results, and the company raised its 2026 revenue outlook to $1.18 billion–$1.28 billion.
• Analyst sentiment is generally positive, with the stock carrying a “Moderate Buy” consensus and an average price target of $95.75, although insiders sold nearly $16.3 million of shares over the past three months and the company remains unprofitable on a reported basis.

Dimensional Fund Advisors LP boosted its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 42.0% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 890,715 shares of the biopharmaceutical company's stock after buying an additional 263,623 shares during the period. Dimensional Fund Advisors LP owned 1.07% of PTC Therapeutics worth $60,674,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of PTCT. UMB Bank n.a. purchased a new stake in PTC Therapeutics during the 4th quarter valued at approximately $26,000. Comerica Bank lifted its holdings in shares of PTC Therapeutics by 868.5% in the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 469 shares in the last quarter. Salomon & Ludwin LLC purchased a new position in shares of PTC Therapeutics in the fourth quarter worth $41,000. Allworth Financial LP boosted its position in shares of PTC Therapeutics by 63.8% during the fourth quarter. Allworth Financial LP now owns 634 shares of the biopharmaceutical company's stock worth $48,000 after acquiring an additional 247 shares during the last quarter. Finally, First Horizon Corp bought a new position in shares of PTC Therapeutics during the fourth quarter worth $53,000.

PTC Therapeutics Stock Performance

Shares of PTCT stock opened at $68.01 on Friday. PTC Therapeutics, Inc. has a 52-week low of $43.17 and a 52-week high of $90.87. The firm has a market capitalization of $5.64 billion, a P/E ratio of -117.26, a P/E/G ratio of 5.92 and a beta of 0.53. The stock has a 50 day moving average price of $77.57 and a 200 day moving average price of $72.74.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.24 by $0.68. The business had revenue of $360.52 million for the quarter, compared to analyst estimates of $298.63 million. PTC Therapeutics had a negative return on equity of 362.45% and a negative net margin of 3.80%.The business's revenue was up 101.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.83) earnings per share. As a group, sell-side analysts forecast that PTC Therapeutics, Inc. will post 0.41 EPS for the current year.

PTC Therapeutics News Summary

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC Therapeutics reported second-quarter revenue of approximately $361 million, including $239 million in product revenue, up 101.5% year over year. Adjusted earnings of $0.92 per share exceeded consensus expectations, while the company moved from a year-ago loss to a profit. PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Sephience (sepiapterin) generated $151 million in second-quarter revenue, with management citing continued broad adoption and international expansion. This performance supports the drug’s role as a key commercial growth driver. Corporate Update and Financial Results
• Positive Sentiment: The company raised its full-year 2026 outlook, projecting total revenue of $1.18 billion to $1.28 billion and product revenue of $850 million to $950 million. PTC also reported a substantial cash balance of $2.2 billion at June 30, providing financial flexibility. Corporate Update and Financial Results
• Neutral Sentiment: The earnings call and follow-up analysis frame PTC Therapeutics as entering a strategically important phase, with investors focused on Sephience’s continued launch trajectory, additional pipeline opportunities and execution against the updated financial targets. PTC Therapeutics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the headline beat and raised guidance, the stock’s reaction suggests investors may have been expecting even stronger results or a more aggressive outlook. PTC remains unprofitable on a reported basis, with a negative net margin, leaving valuation sensitive to sustained commercial growth and pipeline execution. PTC Therapeutics Q2 Key Metrics Versus Estimates

Insider Activity at PTC Therapeutics

In related news, insider Neil Gregory Almstead sold 2,464 shares of the company's stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $90.25, for a total value of $222,376.00. Following the completion of the sale, the insider directly owned 60,299 shares of the company's stock, valued at $5,441,984.75. This represents a 3.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Mark Elliott Boulding sold 5,079 shares of the company's stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $85.08, for a total transaction of $432,121.32. Following the completion of the sale, the vice president directly owned 105,272 shares of the company's stock, valued at approximately $8,956,541.76. This trade represents a 4.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 198,662 shares of company stock worth $16,347,994 over the last three months. 5.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Morgan Stanley increased their price objective on shares of PTC Therapeutics from $93.00 to $104.00 and gave the company an "overweight" rating in a report on Friday. Jefferies Financial Group upgraded PTC Therapeutics from a "hold" rating to a "buy" rating and boosted their target price for the stock from $76.00 to $85.00 in a research report on Wednesday, May 27th. TD Cowen raised PTC Therapeutics from a "hold" rating to a "buy" rating and increased their price target for the company from $75.00 to $90.00 in a research note on Friday, May 8th. Weiss Ratings upgraded PTC Therapeutics from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday. Finally, Citigroup upgraded PTC Therapeutics from a "neutral" rating to a "buy" rating and raised their price target for the company from $75.00 to $108.00 in a report on Tuesday, June 9th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $95.75.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.

Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.